WEKO3
アイテム
Effective treatment of a 13-year-old boy with steroid-dependent ocular myasthenia gravis using tacrolimus
https://tokushima-u.repo.nii.ac.jp/records/2007805
https://tokushima-u.repo.nii.ac.jp/records/2007805af59dc4b-ce38-4057-b166-75268e263d8f
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
braindev_35_5_445.pdf (658 KB)
|
|
| Item type | 文献 / Documents(1) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2020-06-24 | |||||||||||||||||
| アクセス権 | ||||||||||||||||||
| アクセス権 | open access | |||||||||||||||||
| 資源タイプ | ||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||
| 出版社版DOI | ||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||
| 関連識別子 | https://doi.org/10.1016/j.braindev.2012.06.012 | |||||||||||||||||
| 言語 | ja | |||||||||||||||||
| 関連名称 | 10.1016/j.braindev.2012.06.012 | |||||||||||||||||
| 出版タイプ | ||||||||||||||||||
| 出版タイプ | AM | |||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||||||||||||||
| タイトル | ||||||||||||||||||
| タイトル | Effective treatment of a 13-year-old boy with steroid-dependent ocular myasthenia gravis using tacrolimus | |||||||||||||||||
| 言語 | en | |||||||||||||||||
| 著者 |
森, 達夫
× 森, 達夫× 森, 健治
WEKO
1564
× 鈴江, 真史× 伊藤, 弘道× 香美, 祥二
WEKO
1631
|
|||||||||||||||||
| 抄録 | ||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||
| 内容記述 | Over the past several years, tacrolimus has attracted attention as a new therapeutic drug for myasthenia gravis (MG), but few reports have considered its use for MG in pediatric patients, and most of these have focused on severe systemic MG. In this case report, we used tacrolimus to successfully treat a 13-year-old boy with ocular MG who had suffered from severe steroid complications, including a failure of thrive and osteoporosis. He first showed symptoms of ocular MG at age 2 years 3 months. At age 13 years, he was receiving PSL (3.75 mg/day), but the symptoms of ocular MG recurred. We increased the dosage of oral PSL up to 30 mg/day, and three courses of mPSL pulse therapy were applied, but these therapies had only limited effect, and his symptoms worsened. Tacrolimus was started at 0.4mg/day (0.011mg/kg/day), and every two weeks the dose was gradually increased by 0.2mg/day. His symptoms of MG began to improve three weeks after the initial administration of tacrolimus. Approximately three months after the start of tacrolimus administration, PSL was discontinued. Currently, at one year and four months after the start of tacrolimus administration, while slight ptosis is observed in the evening, it does not influence his daily life, and his condition remains comparable to that when he stopped taking PSL. No adverse effects of tacrolimus have been recognized. In pediatric patients with steroid-dependent ocular MG without thymectomy, tacrolimus may be a safe and effective alternative to steroid and thymectomy. | |||||||||||||||||
| 言語 | en | |||||||||||||||||
| キーワード | ||||||||||||||||||
| 言語 | en | |||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||
| 主題 | Tacrolimus | |||||||||||||||||
| キーワード | ||||||||||||||||||
| 言語 | en | |||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||
| 主題 | Ocular myasthenia | |||||||||||||||||
| キーワード | ||||||||||||||||||
| 言語 | en | |||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||
| 主題 | Childhood | |||||||||||||||||
| キーワード | ||||||||||||||||||
| 言語 | en | |||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||
| 主題 | Steroid-resistant | |||||||||||||||||
| 書誌情報 |
en : Brain and Development 巻 35, 号 5, p. 445-448, 発行日 2012-07-26 |
|||||||||||||||||
| 収録物ID | ||||||||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||||||||
| 収録物識別子 | 03877604 | |||||||||||||||||
| 収録物ID | ||||||||||||||||||
| 収録物識別子タイプ | NCID | |||||||||||||||||
| 収録物識別子 | AA00111153 | |||||||||||||||||
| 収録物ID | ||||||||||||||||||
| 収録物識別子タイプ | NCID | |||||||||||||||||
| 収録物識別子 | AA11521714 | |||||||||||||||||
| 出版者 | ||||||||||||||||||
| 出版者 | The Japanese Society of Child Neurology | |||||||||||||||||
| 言語 | en | |||||||||||||||||
| 出版者 | ||||||||||||||||||
| 出版者 | Elsevier | |||||||||||||||||
| 言語 | en | |||||||||||||||||
| 権利情報 | ||||||||||||||||||
| 言語 | en | |||||||||||||||||
| 権利情報 | © 2012. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | |||||||||||||||||
| EID | ||||||||||||||||||
| 識別子 | 280470 | |||||||||||||||||
| 識別子タイプ | URI | |||||||||||||||||
| 言語 | ||||||||||||||||||
| 言語 | eng | |||||||||||||||||
